Compare CVS Health Corp (CVS) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Entegris Inc — how do they compare? CVS Health Corp trades at $86.3 (market cap $112.49B), while Entegris Inc trades at $165 (market cap $25.41B). The key difference: CVS Health Corp is far larger — about 4.4× Entegris Inc's market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Entegris Inc for 41 Days on average.
| CVS | ENTG | |
|---|---|---|
Market Cap | $112.49B | $25.41B |
Volume | 8,467,392 | 2,160,232 |
Sector | Health | Technology |
52-Week High | $110.60 | $184.00 |
52-Week Low | $70.08 | $68.80 |
Typical Hold Time | 83 Days | 41 Days |
Enterprise Value | $174.83B | $28.62B |
Dividend Yield | 3.02% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
ENTG trades at $162.19, down 2.82% today, with strong technical momentum as moving averages signal bullish alignment. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $0.93 versus $0.82, driven by AI-related semiconductor demand. Revenue remains stable at $3.2B in 2025, while net income margin improved to 9.18% in 2026 projections. Recent institutional buying includes BlackRock's $3.68 billion position, reflecting confidence in Entegris' advanced materials leadership.
Outlook remains positive with analyst consensus target of $182.43 suggesting 12.5% upside, supported by 70% buy ratings. Key risks include high valuation multiples (P/E 83.16) and semiconductor cycle sensitivity. The upcoming Q3 earnings on October 29, 2026, and Investor Day on November 9, 2026, are critical catalysts for confirming growth trajectory amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
